Blood stream infections (BSIs) are a significant cause of morbidity and mortality in the USA. While the true incidence of nosocomial BSIs is unknown, several studies have reported that an estimated 250,000 cases occur annually. There is evidence to show that early and appropriate antimicrobial therapy is an important contributor to a favorable outcome for patients with BSI. Current diagnostic methods can take from 24 hours up to a week or more for positive pathogen identification and characterization. The reduction of the time period from specimen collection until the availability of species identification and antimicrobial susceptibility is therefore critical in improving outcomes for patients with severe bloodstream infections. No molecular diagnostic tool is currently available to clinical microbiology laboratories that have been validated against the existing gold standard methods for pathogen identification, and susceptibility testing. We plan to develop in close collaboration with bioMerieux, a global leader in clinical diagnostics, a next-generation nucleic acid based NASBA-Molecular Beacons platform for rapid identification of bacterial and fungal pathogens, and associated drug resistance in selected organisms. Three clinical sites in New York (USA), Toronto (CAN) and Manchester (UK) have been selected to evaluate the new platform in relation to an existing culturebased gold standard. These large tertiary care medical centers will create a robust environment to conduct the studies. They all provide complex intensive care services (greater than 300 beds total) to highly diverse at risk populations, have leading infectious diseases clinical researchers, and a clinical microbiology laboratory with the expertise and the experience necessary to conduct the evaluation. This comprehensive approach joining PHRI's technical expertise in molecular beacon probe development with bioMerieux NASBA technology and clinical diagnostic product development, along with outstanding clinical partners will help ensure that a product applicable to improving Sepsis outcome will emerge. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
6U01AI066561-03
Application #
7222711
Study Section
Special Emphasis Panel (ZAI1-SR-M (M1))
Program Officer
Korpela, Jukka K
Project Start
2005-07-14
Project End
2010-03-31
Budget Start
2006-12-19
Budget End
2007-03-31
Support Year
3
Fiscal Year
2006
Total Cost
$181,054
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
623946217
City
Newark
State
NJ
Country
United States
Zip Code
07107
Astvad, Karen M; Perlin, David S; Johansen, Helle K et al. (2013) Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species. Antimicrob Agents Chemother 57:177-82
Zhao, Yanan; Perlin, David S (2013) Quantitative detection of Aspergillus spp. by real-time nucleic acid sequence-based amplification. Methods Mol Biol 968:83-92
Harrison, E; Singh, A; Morris, J et al. (2012) Mannose-binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis. Int J Immunogenet 39:224-32
Zhao, Yanan; Paderu, Padmaja; Park, Steven et al. (2012) Expression turnover profiling to monitor the antifungal activities of amphotericin B, voriconazole, and micafungin against Aspergillus fumigatus. Antimicrob Agents Chemother 56:2770-2
Denning, David W; Park, Steven; Lass-Florl, Cornelia et al. (2011) High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 52:1123-9
Zhao, Yanan; Park, Steven; Warn, Peter et al. (2010) Detection of Aspergillus fumigatus in a rat model of invasive pulmonary aspergillosis by real-time nucleic acid sequence-based amplification. J Clin Microbiol 48:1378-83
Pfeiffer, Christopher D; Garcia-Effron, Guillermo; Zaas, Aimee K et al. (2010) Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 48:2373-80
Zhao, Yanan; Park, Steven; Kreiswirth, Barry N et al. (2009) Rapid real-time nucleic Acid sequence-based amplification-molecular beacon platform to detect fungal and bacterial bloodstream infections. J Clin Microbiol 47:2067-78
Perlin, David S; Zhao, Yanan (2009) Molecular diagnostic platforms for detecting Aspergillus. Med Mycol 47 Suppl 1:S223-32
Perlin, David S (2009) Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis 22:568-73

Showing the most recent 10 out of 13 publications